Cargando…
18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
PURPOSE: [18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT) is used for diagnosis, staging, response assessment and prognosis prediction in different tumors, but its role in esophageal cancer is still debated. The aim of this study was to evaluate the role o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016048/ https://www.ncbi.nlm.nih.gov/pubmed/35275345 http://dx.doi.org/10.1007/s12149-022-01733-9 |
_version_ | 1784688445252173824 |
---|---|
author | Krengli, Marco Ferrara, Eleonora Guaschino, Riccardo Puta, Erinda Turri, Lucia Luciani, Ilaria Sacchetti, Gian Mauro Franco, Pierfrancesco Brambilla, Marco |
author_facet | Krengli, Marco Ferrara, Eleonora Guaschino, Riccardo Puta, Erinda Turri, Lucia Luciani, Ilaria Sacchetti, Gian Mauro Franco, Pierfrancesco Brambilla, Marco |
author_sort | Krengli, Marco |
collection | PubMed |
description | PURPOSE: [18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT) is used for diagnosis, staging, response assessment and prognosis prediction in different tumors, but its role in esophageal cancer is still debated. The aim of this study was to evaluate the role of semiquantitative baseline PET parameters as possible prognostic and predictive factors in a series of esophageal carcinomas treated with combined modalities. METHODS: 43 patients with esophageal carcinoma were treated with chemoradiotherapy (CRT) followed by surgery in 20 cases and underwent pre-treatment 18F-FDG-PET/CT. Semiquantitative PET parameters were evaluated including Standardized Uptake Value (SUVmax e SUVmean), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) with isocontour of 41 and 50%. Further variables analyzed were gender, primary tumor site, histological type, use of surgery, achievement of a radical resection and the type of chemotherapy regimen. The correlation of all variables with treatment response, loco-regional control (LR), Overall survival (OS) and Disease-Free Survival (DFS) was evaluated. RESULTS: SUVmax, SUVmean50 and SUVmean41 were significantly higher in node-positive cases and in squamous cell carcinomas. With respect to prognostic factors, MTV was found to be correlated with OS: patients with MTV41 < 11.32 cm(3) and MTV50 < 8.07 cm(3) (both p values = 0.04) showed better 3-year OS rates (33 vs. 20%). Further factors predicting a better prognosis were the use of surgery and radical resection (R0) (both p values < 0.01). CONCLUSIONS: Pre-treatment MTV values were significant prognostic factors for OS, together with the use of surgery and R0 resection in esophageal cancers treated with multimodal therapies. |
format | Online Article Text |
id | pubmed-9016048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-90160482022-05-02 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment Krengli, Marco Ferrara, Eleonora Guaschino, Riccardo Puta, Erinda Turri, Lucia Luciani, Ilaria Sacchetti, Gian Mauro Franco, Pierfrancesco Brambilla, Marco Ann Nucl Med Original Article PURPOSE: [18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT) is used for diagnosis, staging, response assessment and prognosis prediction in different tumors, but its role in esophageal cancer is still debated. The aim of this study was to evaluate the role of semiquantitative baseline PET parameters as possible prognostic and predictive factors in a series of esophageal carcinomas treated with combined modalities. METHODS: 43 patients with esophageal carcinoma were treated with chemoradiotherapy (CRT) followed by surgery in 20 cases and underwent pre-treatment 18F-FDG-PET/CT. Semiquantitative PET parameters were evaluated including Standardized Uptake Value (SUVmax e SUVmean), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) with isocontour of 41 and 50%. Further variables analyzed were gender, primary tumor site, histological type, use of surgery, achievement of a radical resection and the type of chemotherapy regimen. The correlation of all variables with treatment response, loco-regional control (LR), Overall survival (OS) and Disease-Free Survival (DFS) was evaluated. RESULTS: SUVmax, SUVmean50 and SUVmean41 were significantly higher in node-positive cases and in squamous cell carcinomas. With respect to prognostic factors, MTV was found to be correlated with OS: patients with MTV41 < 11.32 cm(3) and MTV50 < 8.07 cm(3) (both p values = 0.04) showed better 3-year OS rates (33 vs. 20%). Further factors predicting a better prognosis were the use of surgery and radical resection (R0) (both p values < 0.01). CONCLUSIONS: Pre-treatment MTV values were significant prognostic factors for OS, together with the use of surgery and R0 resection in esophageal cancers treated with multimodal therapies. Springer Nature Singapore 2022-03-11 2022 /pmc/articles/PMC9016048/ /pubmed/35275345 http://dx.doi.org/10.1007/s12149-022-01733-9 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Krengli, Marco Ferrara, Eleonora Guaschino, Riccardo Puta, Erinda Turri, Lucia Luciani, Ilaria Sacchetti, Gian Mauro Franco, Pierfrancesco Brambilla, Marco 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment |
title | 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment |
title_full | 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment |
title_fullStr | 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment |
title_full_unstemmed | 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment |
title_short | 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment |
title_sort | 18f-fdg pet/ct as predictive and prognostic factor in esophageal cancer treated with combined modality treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016048/ https://www.ncbi.nlm.nih.gov/pubmed/35275345 http://dx.doi.org/10.1007/s12149-022-01733-9 |
work_keys_str_mv | AT krenglimarco 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT ferraraeleonora 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT guaschinoriccardo 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT putaerinda 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT turrilucia 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT lucianiilaria 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT sacchettigianmauro 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT francopierfrancesco 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment AT brambillamarco 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment |